TCM
ALT icon

Tekla Capital Management’s Altimmune ALT Stock Holding History

Tekla Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$265K Hold
75,000
– – 0.01% 152
2023
Q1 		$317K Buy
+75,000
New +$891K 0.01% 158

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Tekla Capital Management's ALT Position: Q2 2023 in Review

Tekla Capital Management held its Altimmune (ALT) position steady in Q2 2023 at 75,000 shares worth $265K. The position accounts for 0.01% of the portfolio, ranked #152.

Tekla Capital Management first reported a position in ALT in Q1 2023 and has held it in 2 quarters since. The position peaked at $317K in Q1 2023. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

  • Tekla Capital Management held 75,000 shares of Altimmune worth $265K as of Q2 2023.
  • Tekla Capital Management left its Altimmune share count unchanged in Q2 2023.
  • Altimmune made up 0.01% of Tekla Capital Management's portfolio in Q2 2023, its #152 holding.
  • Tekla Capital Management first reported a position in Altimmune in Q1 2023 and has held it in 2 quarters since.
  • Tekla Capital Management's Altimmune position peaked at $317K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.